Back to search results

Inspiratory Muscle Strength Training for Chronic Kidney Disease and High Blood Pressure

This study is looking at whether Inspiratory Muscle Strength Training (IMST) can help lower high blood pressure in people with chronic kidney disease (CKD). IMST uses a handheld device to strengthen breathing muscles. You might be able to join if you are 50 or older, a woman who has gone through menopause, have moderate to severe CKD, and have high blood pressure that isn't well-controlled. The study will measure changes in your casual systolic blood pressure (the top number in a blood pressure reading) after 3 months to see if IMST is effective. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 108 participants. It compares Inspiratory Muscle Strength Training (IMST) to Sham Training.
What's involved
Participants will perform IMST or Sham Training using a handheld device for 30 minutes per week (5 minutes a day, 6 days a week). Blood pressure will be measured at the start and after 3 months.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 3 months, indicating a follow-up period of at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04911491

Inspiratory Muscle Strength Training in Chronic Kidney Disease

Recruiting
NAAges 50+InterventionalTreatment
University of Colorado, Denver
~108 participants
Updated 2025-05-02 on ClinicalTrials.gov
What's tested:IMSTSham Training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Casual Systolic Blood Pressure
Measured over Baseline, 3 months

Conditions

Chronic Kidney Diseases
Hypertension
Aging
Blood Pressure

Explore related trials

Chronic Kidney DiseaseHypertension

Where it's being run

1 sites across 1 states
Colorado1

Study leadership

  • Kristen Nowak, PhD, MPH · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
  • Michel Chonchol, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

Kristen Nowak, PhD, MPH
[email protected]
303-724-4842
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 50 years or older; women must be post-menopausal
Chronic kidney disease stage 3 or 4 (estimated glomerular filtration rate with the 4 CKD-EPI 2021 race-free equation: 20-59 mL/min/1.73m\^2; stable renal function in the past 3 months)
History of inadequately controlled hypertension (systolic blood pressure 120-159 mmHg on two separate days) and on a stable antihypertensive regimen for the past 6 weeks
Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study. Participants using glucagon-like peptide-1 receptor agonists or planning to start them during the study are excluded unless they have achieved weight stability for at least 3 months prior to enrollment.
Ability to provide informed consent

Exclusion

Patients with advanced chronic kidney disease requiring chronic dialysis
Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma
History of spontaneous pneumothorax, collapsed lung due to traumatic injury that has not fully healed, burst eardrum that has not fully healed, or other conditions of the eardrum
Significant co-morbid conditions with a life expectancy of \< 1 year
History of severe congestive heart failure (i.e., ejection fraction \<35%)
History of hospitalization within the last month
Albuminuria (albumin to creatinine ratio \> 2200 mg/g
Current smoker
Immunosuppressant agents taken in the past 12 months. Steroids used for the treatment of gout are acceptable; however, patients should not be using steroids within 2 weeks (or 14 days) prior to the vascular testing (rationale: may confound vascular testing)
Known malignancy
Inability to cooperate with or clinical contraindication for magnetic resonance imaging including: severe claustrophobia, implants, devices, or non-removable body piercings (these individuals can participate in the study but are excluded from the MRI procedure)
Illicit drug use or alcohol dependence/abuse, which in the opinion of the investigators, would prohibit compliance with the study intervention

What this trial measures

  • Change in Casual Systolic Blood PressureBaseline, 3 months

    Casual (resting) measures of systolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer.